Publication Name	World Journal of Gastrointestinal Pharmacology and Therapeutics
Manuscript ID	29077
Country	Italy

Received	2016-07-28 10:05
Peer-Review Started	2016-07-29 16:55
To Make the First Decision	2016-10-20 08:40
Return for Revision	2016-10-20 14:29
Revised	2016-10-28 20:02
Second Decision	2017-01-04 15:54
Accepted by Journal Editor-in-Chief	2017-01-04 23:42
Accepted by Company Editor-in-Chief	2017-01-14 14:25
Articles in Press	2017-01-14 14:25
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2017-04-28 10:07
Publish the Manuscript Online	2017-05-04 08:16

ISSN	2150-5349 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Minireviews
Article Title	Inflammatory bowel disease: Efficient remission maintenance is crucial for cost containment
Manuscript Source	Invited Manuscript
All Author List	Giovanni C Actis and Rinaldo Pellicano
Funding Agency and Grant Number
Corresponding Author	Giovanni C Actis, MD, the Medical Center Practice Office, 10129 Torino, Italy. actis_g@libero.it
Key Words	Inflammatory bowel disease; Therapy; Cost containment; Budget; Treatment adherence; Inflammatory bowel disease managed care
Core Tip	Cost-effective maintenance of remission of inflammatory bowel diseases (IBD) is a traditionally unsolved challenge for care-takers and budget supervisors. The newly released (biologic) formulations, though purported to act as disease terminators, have failed to pay back their initial cost. We have faced the issue by reappraising initial simple tenets and found the following: (1) usually, uncomplicated IBD rests in remission by using cheap traditional drugs, provided the indication is correct, and, chiefly, that adherence is tightly maintained. Non compliant IBD patients cost manifold the compliant ones, and are the main cause of budget distortion; and (2) third-party drugs (nonsteroidal anti-inflammatory drugs, e.g., should be avoided. A frozen steady-state is the regime to effectively maintain IBD.
Publish Date	2017-05-04 08:16
Citation	Actis GC, Pellicano R. Inflammatory bowel disease: Efficient remission maintenance is crucial for cost containment. World J Gastrointest Pharmacol Ther 2017; 8(2): 114-119
URL	http://www.wjgnet.com/2150-5349/full/v8/i2/114.htm
DOI	http://dx.doi.org/10.4292/wjgpt.v8.i2.114

Full Article (PDF)	WJGPT-8-114.pdf
Full Article (Word)	WJGPT-8-114.doc
Manuscript File	29077-Review.doc
Answering Reviewers	29077-Answering reviewers.pdf
Audio Core Tip	29077-Audio core tip.wma
Conflict-of-Interest Disclosure Form	29077-Conflict-of-interest statement.pdf
Copyright License Agreement	29077-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	29077-Language certificate.pdf
Peer-review Report	29077-Peer-review(s).pdf
Journal Editor-in-Chief Review Report	29077-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	29077-Scientific misconduct check.pdf
Scientific Editor Work List	29077-Scientific editor work list.pdf